fbpx

Written by 08:00 Okategoriserade

Simris set for commercial acceleration in 2022 | See interview with Chairman Steven Schapera

Besides heading a 100 MUSD SPAC just listed on the NYSE, Simris Alg’s Chairman Steven Schapera has now gotten Simris on the right keel and is looking to accelerate commercial activity focussing on B2B-customers in nutrition, cosmetics and pharma, unlockling a 3x revaluation to get on par with peers and well beyond that in the long term. See interview with Simris’ Chairman about the outlook for Simris and the potential in the algae market.

Johan Widmark | 2021-12-16 08:00

This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.  
 
Sold more product than in the company’s lifetime

In May 2021, internationally renowned cosmetics veteran Steven Schapera took on the position of chairman of Simris Alg, after joining the company as its largest shareholder back in 2020. Along with the subsequent departure of Simris’ founder and former CEO, Fredrika Gullström, this was the starting point for a refocussing of the company, away from research without clear commercial purpose, towards creating products based on Simris’ knowhow around growing micro algae, for which there is a demand.

– Very quickly, with the relationship I have in the micro algae space, I was able to find a customer for the fucoxanthin. It’s almost hard to believe, but in the last few months and with the orders at hand, I think we’ve sold more product than the company has sold in its lifetime, says Steven Schapera.

After having spent the last half year stabilizing the ship, Steven Schapera expects to have eliminated considerable cost by end of December and set the company up for growth with new strategic relationships. With regards to targets for 2022, Schapera is clearly focused on creating wealth for shareholders and generate revenues.

– Everything I do today has to be aimed at ultimately generating revenue. Our business model has changed, from being a D2C focussed selling omega-3 products primarily in North America, to being a B2B selling very high value actives extracted from micro algae that can be used in the nutrition, cosmetic, skincare and haircare space, as well as pharmaceutical. 

Considerable revaluation potential

In the interview, Steven Schapera also elaborates on the valuation of Simris Alg, where he sees a very favourable comparison with other algae companies internationally.

– If you wanted to replace Simris today, my best guess is that it would cost you 20 MEUR. There aren’t a lot of micro algae companies that are being sold, but I get to see the investor decks on most of them. Even conceptual companies, meaning that they haven’t even proven their concept yet, enjoy valuations well north of 20 MEUR.

Read more about Simris Alg here 

Combined with a discounted cash flow approach, which is difficult in the case of Simris, Schapera argues that a triangulation of replacement, peer and discounted cashflows valuations support a value at around 18-22 MEUR. This compares to Simris valuation at around 6-7 MEUR.

International heavy hitter in the wellness space

London-based Steven Schapera founded the successful BECCA Cosmetic brand and commercialised it into a range of cosmetic products that were distributed throughout Europe, North America and Asia, before BECCA was sold for over 230 MUSD to Estee Lauder in 2016. Apart from his engagement as Chairman of Simris Alg, Steven Schapera is involved in two listed Australian companies, in Wellfully as non-executive director, and Crowd Media listed in the Netherlands, where he is chairman. Schapera is also CEO of a SPAC named Integrated Wellness Acquisition Corp, that was listed at the New York Stock Exchange earlier in December when it raised 100 MUSD in an IPO that was oversubscribed by 7x.

– The turnaround we have been working on is very expensive. Sweden is an expensive country in which to make changes to a company. Sometime in Q1 2022, we will do another capital raising, and hopefully at that time we will have demonstrated to shareholders and potential investors that the ship is indeed upright and pointing in the right direction. Then there will be a compelling reason for investors to participate.

DISCLAIMER

GENERAL DISCLAIMER AND COPYRIGHT

This commissioned research report is for informational purposes only and is to be considered marketing communication. This research does not constitute investment advice and is not a solicitation to buy shares. Information provided here or on Emergers’ website emergers.se is not intended to be financial advice. This research shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers standard fees are SEK 240,000 pa for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest.

Copyright: Copyright 2021 Incirrata AB (Emergers)

United Kingdom
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Be first to read new research on growth stocks